NCT01957306已完成2 期
A Phase 2, Open Label Clinical Trial Assessing Safety and Efficacy of Dr. Tagliaferri's Menopause Formula for Hot Flushes and Menopausal Symptoms in Postmenopausal Women
Herba Buena, Inc2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2013年11月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Change in frequency of moderate to severe hot flushes from baseline to 12 weeks.
研究概览
简要总结
The primary goal of this study is to evaluate the safety and efficacy of 12 weeks of treatment of 4 grams/day of Dr. Tagliaferri's Menopause Formula (administered as 2 grams PO BID) in reducing the frequency of menopausal vasomotor symptoms among healthy, postmenopausal women, aged 40-65, with moderate to severe hot flushes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Provide written informed consent.
- •Postmenopausal women aged 40-65 years.
- •Postmenopausal as defined by one of the following criteria:
- •12 months of spontaneous amenorrhea;
- •6 months of spontaneous amenorrhea with serum FSH >30 mIU/ml;
- •6 weeks of surgical amenorrhea following bilateral oophorectomy with or without hysterectomy; or
- •hysterectomy alone with serum FSH >30 mIU/ml.
- •During Screening, the patient must report they are having at least 5 moderate to severe hot flashes per day or 35 moderate to severe hot flashes per week.
- •On the Screening Hot Flush Diary, demonstrate compliance (by indicating they filled out the diary "all of the time" or "most of the time") on at least 4 out of 7 days.
- •Currently receive medical care from a health care provider.
排除标准
- •History of malignancy, with the exception of non-melanoma skin cancer or cervical cancer that was diagnosed with treatment completion more than 1 year prior to screening (i.e., if a participant had cervical cancer or basal cell carcinoma that was diagnosed and fully treated 2 years prior to screening, the participant would be eligible for the study).
- •Known carrier of BRCA1 or BRCA
- •Within 12 months of screening, abnormal mammogram or breast examination that is suggestive of cancer, or refused mammogram or breast exam.
- •Within 12 months of screening, abnormal Pap smear or pelvic examination that is suggestive of cancer, or refused Pap smear or pelvic exam.
- •Transvaginal Ultrasound (TVUS) double-wall endometrium of >8mm on TVUS.
- •Participants with polyps or other abnormal uterine masses (with the exception of fibroids) on TVUS.
- •Unexplained uterine bleeding within six months prior to screening.
- •Clinical evidence of active ischemic cardiovascular disease or history of cardiovascular disease.
- •Uncontrolled hypertension (≥160/100 at baseline or within 4 weeks prior to screening) or a history of transient ischemic attack or cerebrovascular accidents.
- •History of deep vein thrombosis or pulmonary embolism.
- •Active liver disease or a history of impaired hepatic function.
- •History of chronic hepatitis B or C, hepatitis within the past 3 months, or HIV infection.
- •History of severe chronic diarrhea, chronic constipation, uncontrolled irritable bowel syndrome (IBS), uncontrolled inflammatory bowel disease (IBD), or unexplained weight loss.
- •Active gallbladder disease.
- •Use of prescription medications known to be possibly effective for the treatment of hot flushes within: 1 week prior to screening for vaginal hormonal products (rings, creams, gels), 4 weeks prior to screening for transdermal estrogen alone or estrogen/progestin products, 4 weeks prior to screening for testosterone products (oral, patch, gel or cream), 8 weeks prior to screening for oral estrogen and/or progestin therapy and intrauterine progestin therapy, 3 months prior to screening for progestin implants and estrogen alone injectable drug therapy and 6 months prior to screening for estrogen pellet therapy or progestin injectable drug therapy.
- •Use of herbal or dietary supplements purported to treat hot flushes or herbal/dietary supplements with known estrogenic or progestogenic activity within 2 weeks of screening.
- •Use of herbal or dietary supplements within 2 weeks prior to screening, unless the participant agrees not to change the frequency or dose of the herbal supplement for the entire duration of study treatment.
- •Currently taking morphine or other opiates on a chronic basis.
- •Any laboratory findings out of normal range deemed clinically significant.
- •BMI >35 kg/m2
- •History of substance abuse within the past year.
- •Use of another investigational agent within 1 month prior to screening.
- •History of severe food or medicine allergies resulting in anaphylactic shock, requiring hospitalization, or requiring use of epinephrine.
- •Any concern or medical, emotional or psychiatric condition that, in the investigator's opinion, would preclude the participant from providing informed consent, completing questionnaires, adhering to the protocol or completing the trial (e.g., severe illness, plans to move, substance abuse, significant psychiatric problems, or dementia).
结局指标
主要结局
Change in frequency of moderate to severe hot flushes from baseline to 12 weeks.
时间窗: 12 weeks
次要结局
- Adverse events assessment(12 weeks)
- Change in the frequency of hot flushes that awake participants during sleep(12 weeks)
- Change in frequency of moderate to severe hot flushes from baseline to week 4(4 weeks)
- Change in severity of moderate to severe hot flushes from baseline to week 4(4 weeks)
- Change in severity of moderate to severe hot flushes from baseline to week 12(12 weeks)
- The clinical meaningfulness of the reduction in hot flashes(12 weeks)
- Change in weight and body mass index (BMI) from baseline compared to study termination(12 weeks)
- change in blood pressure from baseline compared to study termination.(12 weeks)
- Adherence to study medication based on pill counts(12 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.Hepatitis BNCT00044135Triangle Pharmaceuticals30
已完成
2 期
CX-8998 for Absence SeizuresEpilepsyNCT03406702Jazz Pharmaceuticals7
已完成
1 期
Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b ParticipantsChronic Hepatitis C InfectionNCT01700179Alexion Pharmaceuticals, Inc.8
已完成
2 期
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 InfectionHepatitis C VirusNCT02349048Janssen Research & Development, LLC68
已完成
2 期
Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV ParticipantsHepatitis C, ChronicNCT01849562Alexion Pharmaceuticals, Inc.30